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Background: The existence of gender-related differences since childhood in survival of cystic fibrosis (CF) patients has been recently challenged.
Methods: We evaluated the effect of gender on survival of 2293 CF patients born after 01/01/1988, followed up by 29 CF centres until 31/12/2004
and recorded in the Italian Registry for CF (IRCF).
Results: We observed similar annual mortality rates in females (3.59‰) and males (4.00‰), similar survival curves (log-rank test p=0.64) and
similar hazards of death (hazard ratio adjusted for presence of symptoms at diagnosis, meconium ileus, F508del mutation and age at diagnosis:
1.29, 95%CI: 0.60; 2.76). However, excess mortality due to CF was higher for females (5.9) than males (5.1).
Conclusions: In our population CF females do not experience higher mortality than males but, due to the disease, they lose the expected survival
advantage occurring in the general population at this age. We do not exclude, however, that differences in mortality will establish after adolescence.
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The severity of cystic fibrosis (CF) is highly variable and
may be influenced by numerous factors including mutations in
the CFTR gene, genetic background, pancreatic status, age and
symptoms at diagnosis, chronic pulmonary infections due to
specific microorganisms, metabolic complications, and social
conditions [1]. Gender has also been reported to influence
outcome: females have been reported to die earlier than males,
although no exhaustive explanation is available [2–4]. Recent
data, from single centres, have challenged this view suggesting
that gender difference in survival [5] or severity [6] of CF is no
longer seen in current practice, at least in younger generations of
patients.
We analyzed the Italian Registry for CF (IRCF), which
collects data from all the Italian CF Centres prospectively since
1988 [7,8] to evaluate whether gender affects survival in the
Italian CF paediatric population.
2. Patients and methods
We analysed data from the subset of 2293 CF patients born
after 01/01/1988 followed up until 31/12/2004 by 29 Italian CF
centres and recorded in the IRCF. We restricted the analysis to
this cohort of patients to avoid selection bias triggered by long-
survivors effect: since the deaths that occurred before 1988 were
necessarily not recorded by the IRCF, survival probability
would be overestimated, because the survivors contribute to the
denominators of the mortality rates, while their dead
contemporaries will be missing from the numerators.
In 1993, a law was put into effect in Italy, stating that at least
one centre specialised in CF care should be set up in each of the
20 Italian regions. The law further gave the CF centres the
exclusivity on giving payment exemptions for the treatments
necessary for CF. This put the CF centres in the privileged
position of seeing most likely at least once all CF patients: due
to the high costs of CF care, it is highly unlikely that a person
diagnosed with CF has never been in contact with one of the 29
paediatric CF centres operating in Italy.
The IRCF therefore based its data collection on the CF
centres, considering each centre an exhaustive source of
information within the region it operated, and aiming at
covering the Italian territory by involving all the existing CF
centres in the data collection.
All the existing CF centres contribute to the IRCF data
collection since 1988, therefore the registry database can be
reasonably considered an unbiased collection of data on CF
patients living in Italy since 1988.The CF centres were asked to report to the IRCF only
patients meeting the CF diagnosis criteria defined by the IRCF
clinicians. In the first years of IRCF activity, only patients with
Chloride values above 60 mmol/L in the sweat test were
included in the registry, then modified inclusion criteria were
adopted [9]. When new cases of CF were yearly transmitted to
the IRCF, adherence to inclusion criteria was checked and in
case of lack of adherence the centres were asked to revise the
data and provide evidence that the criteria were met.
When the IRCF was activated, it included 2007 prevalent CF
cases. Since then, 3061 incident cases (patients newly
diagnosed with CF, who were not necessarily born after 01/
01/1988) have been registered up to 31/12/2004 (date of last
update of the IRCF). Data collected include patients' demo-
graphics, mode of diagnosis, genotype, transplantation status,
date and cause of death, anthropometric measures, pulmonary
function measures and occurrence of complications. For the
purpose of this study, we analysed only the following subset of
data: gender, date of birth, status as of 31/12/2004 (alive, dead,
lost to follow-up), date of death/loss to follow-up, mode of
diagnosis, solid organ transplantation, and genotype.
We used standardised mortality ratios (SMRs) to evaluate
excess mortality due to CF in both sexes using the Italian
population as a reference, as from the annual reports of the
National Institute of Statistics [10].
We performed survival analysis using the Kaplan–Meier
method and Cox regression models to evaluate the effect of
gender on survival, taking into account well known risk factors
and potential confounders such as mode of diagnosis, year of
diagnosis, age at diagnosis and genotype. We included in the
final model the factors that were reported as confounders from
the literature or that we considered confounders from our data
due to the change from crude to adjusted hazard ratio of death.
We used Log-rank tests, likelihood-ratio, Wald, and chi-
square statistics to check statistical significance of the results
obtained. We set the level of significance at pb0.05.
Analyses were performed with SAS (version 9.1.3, SAS
Institute Inc, Cary, NC) and PS Power and Sample Size
Calculations (version 3.0.34).
3. Results
3.1. Main characteristics of patients
Table 1 summarizes the main characteristics of the 2293 CF
paediatric patients (1141 F, 1152 M) included in the IRCF born
after 1988 and followed-up until December 2004. The incidence
of disease certification in the IRCF throughout the years 1988–
Fig. 1. CFTRmutations, by gender, of the 2293 CF patients born after 01/01/1988
included in the Italian Registry for Cystic Fibrosis. Only the 12 most common
mutations, excluding F508del (47.5% in females, 47.2% in males), are shown.
Table 1
Main characteristics of the 2293 CF patients born after 01/01/1988 included in
the Italian Registry for Cystic Fibrosis.
Females Males
Number of patients in the Registry
n 1141 1152
Mean annual incidence of disease certification (per 10,000) 2.55 2.42
Age (years) on 31.12.2004
Min 0.11 0.08
Max 16.99 17.00
Mean 8.59 8.53
s.d. 4.80 4.73
Median 8.68 8.63
At time of diagnosis (%)
Positive at neonatal screening 53.03 50.78
Presence of symptoms 68.60 71.17
Presence of meconium ileus 17.29 15.62
Age (years) at diagnosis
Min at birth at birth
Max 16.01 15.76
Mean 1.09 1.03
s.d. 2.31 2.13
Median 0.20 0.23
Genotype
Number of patients genotyped 1049 1041
Genotype UN/UN (%) 4.58 6.15
Sweat test
n with Chloride values b60 mmol/L (%) 74(6.5) 67
(5.8)
F508del mutation (%)
Homozygotes 23.83 25.65
Compound heterozygotes 47.28 43.13
Neither allele F508del 28.88 31.22
Pancreatic status
Pancreatic insufficiency (%) at last follow-up visit 77.0 73.76
Number of transplants
Lung 8 3
Liver 1 2
Status
Alive 1062 1070
Lost to follow-up 41 40
Dead for CF 35 39
Dead other cause 3 3
Age (years) at death (CF-related)
Min 0.05 0.02
Max 14.77 15.76
Mean 6.80 5.65
s.d. 5.27 5.41
Median 9.24 5.41
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years in females and 2.42 per 10,000 person-years in males
(95% CI for rates difference: −0.007; 0.332 per 10,000). The
pooled incidence estimate, 2.48 per 10,000 person years (95%
CI: 2.38; 2.59), is comparable to 2.36 (95% CI: 2.25; 2.47) per
10,000 person years, incidence estimated with the registry data
over a shorter time period [8]. There were no gender-related
differences in the age at diagnosis, frequency of positive
neonatal screening, presence of symptoms at diagnosis and
occurrence of meconium ileus. We observed similar proportions
of patients showing sweat test values b60 mmol/L for males
(5.8%) and females (6.5%).
Fourteen patients (9 females and 5 males) underwent
pulmonary or liver transplantation. Although there were morefemales in the lung transplanted group, the numbers are too
small to allow statistical comparisons.
The distribution of mutations in the CFTR gene was similar
in males and females: F508del accounts for 47.5% of mutations
in females and 47.2% in males, whereas unknown mutations
account for 17.1% of alleles in females and 18.8% in males.
Fig. 1 shows the distribution by gender of the 12 most frequent
mutations after F508del.
During the observation period, 81 patients (3.6%, 41
females) were lost to follow-up. We therefore checked that
there was not any informative censoring by verifying that the
characteristics of the patients lost to follow-up were similar to
the characteristics of the patients not lost to follow-up. We did
not find any differences in genotype, age at diagnosis and
symptoms at diagnosis. We further analysed for how long the
patients lost to follow-up remained in the study, and the time to
loss to follow-up was similar between sexes (mean for males:
13.2 years, for females: 13.1).3.2. Survival analysis
In the period 1988–2004 the IRCF reports 80 deaths in the
paediatric age (b18 years), and an annual mortality rate of
3.59‰ (95% CI 2.56; 5.02) for females and 4.00‰ (95% CI:
2.92; 5.51) for males. Age on 31st December 2004 was similar
in males and females and, although age at death was slightly
higher in females, this difference was not statistically significant
(median age: 9.24 years females, 5.41 males, p=0.39).
Fig. 2 shows the Kaplan–Meier survival curves, separately
by gender. The graph does not suggest any different pattern of
survival, as further confirmed by the log-rank test (p=0.64):
survival probability at 5 years from birth is 0.987 for females
and 0.983 for males, at 10 years from birth is 0.980 for females
and 0.971 for males.
After correcting for presence of symptoms at diagnosis,
presence of meconium ileus, F508del mutation and age at
diagnosis, females show a hazard of death 29% higher than
males, though the finding is not statistically significant (hazard
ratio: 1.29, 95%CI: 0.60; 2.76). We choose to adjust for these
factors because they are known risk factors and potential
Fig. 2. Kaplan–Meier survival estimates (males vs females) of CF patients born
after 01/01/1988 included in the Italian Registry for Cystic Fibrosis. Log-rank test
0.22, p=0.64. aAt the beginning of the period, bduring the period.
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0.70; 1.77).
However, male CF patients are 5.090 (95% CI: 5.0896;
5.0913) times more likely to die than Italian males without CF
whereas female CF patients are 5.872 (95% CI: 5.8710; 5.8721)
times more likely to die than their non CF counterparts.
Therefore, females showed an excess mortality due to CF 15%
higher than males.
4. Discussion
This is, to the best of our knowledge, the first longitudinal
study run on a national basis, analysing survival of all newly
diagnosed CF patients followed since birth throughout the
paediatric age. Unlike previous studies, we did not find higher
nor earlier mortality in females with respect to males.
Although 81 patients were lost to follow-up, we do not think
that our findings are biased, since the proportion of patients lost
to follow-up and the time to loss at follow-up were similar in
males and females. Moreover, the baseline characteristics of this
group of patients were similar to the patients not lost to follow-
up; therefore we can reasonably assume that the patients not lost
to follow up are representative of the entire population under
study and that the survival patterns of the two groups are not
different.
Although we cannot exclude that the patients lost to follow-
up died, it would be unreasonable to think that death would
have occurred differently in the two genders to such extent as to
bias our results (for example, assuming that all females died and
none of the males did or vice versa).
SMRs revealed that, should the Italian CF population follow
the same mortality patterns as the general population, we would
expect females to have better survival than males. Therefore, we
can speculate that CF has an effect on females that prevents
them from experiencing a better survival.
In older cohorts of patients, higher mortality in females was
reported already in childhood. In the Canadian registry [2], for
years 1970–1989, the cumulative percent survival at 10 years of
age was 89.1% for males and 85.0% for females. The CFFoundation Patient Registry data confirmed the existence of a
gender gap in survival [3]: between 1988 and 1992, females had
higher risk of death than males since 1 year of age and remained
significantly higher until age 20. This analysis was repeated
years later [4] and, although improvement occurred both in
females and in males, the gender gap still persisted in the age
group 2 to 20 years: females had a risk of death 1.76 to 1.27
higher than males in the age from 2–5 years to the age of 16–
20 years. No gender-related differences were seen beyond this
age.
In our study population survival at ten years of age was
higher than that reported in these studies and similar for females
(97.1%) and males (98.0%). There is some indication therefore
that the differential effects of CF on patient's survival have
decreased for more recent birth cohorts, as suggested by an
analysis performed in UK for years 1947–2003 [11].
One reason for this reduction could be a “period effect”. In
our study population a large proportion of patients was
diagnosed by neonatal screening or was diagnosed early
(median age at diagnosis is 2.6 months); we speculate that
early diagnosis, and therefore early treatment, might prevent the
intrinsic gender gap in the severity of CF to manifest: modern
treatments are more effective in prolonging life and eventually
compensate the disadvantage in females. Moreover, screening
programs allow recognising at birth patients with very mild
mutations or totally asymptomatic which were usually diag-
nosed in the adult age.
Genetic background might also play a role in the different
effect of gender on CF survival across countries. The major
mutation F508del usually associated to a severe phenotype is
less common in Italy, respecting a decreasing incidence from
northern to southern regions of the northern hemisphere [12,13].
The proportion of pancreas sufficient patients, a genetically
determined manifestation generally associated to a milder
pulmonary disease, is slightly higher in Italians than in other
populations. A generally “milder” disease could account for
fewer differences in survival between males and females in our
population.
Other factors have been reported to determine a gender
difference in disease progression or severity in CF, such as
decreased pulmonary function, diabetes, and early Pseudomo-
nas aeruginosa colonization [14–17]. All these factors might
play a role in the loss of a female advantage in survival
probability observed in the general population.
Our findings of a lack of gender difference in survival are not
isolated. A survival study performed by the CF Centre of
Verona collecting all patients of north-eastern Italy did not find
any gender difference in survival probability in the long-term
follow-up of a population-based neonatal screening program
implemented since the 1970s [5]. An analysis performed in a
single CF Centre in London [6] compared cross-sectional and
longitudinal studies of CF patients examining a number of
outcome measures including mortality, height, weight, and lung
function. There were no significant differences between genders
and no clear trends could be recognized. The authors suggested
that modern aggressive treatment regimens could have removed
any adverse female gender bias from lung function and
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the age of 16 years should not have equally good lung function
and nutrition as their male counterpart. Consistent with these
findings, some years earlier Lai et al. [18] analyzed the data of
the Wisconsin neonatal screening program. They did not find
any significant gender differences in respiratory symptoms or
chest radiographic severity scores between males and females
during their first 10 years of life, although a disproportionately
high number of males were referred for diagnostic sweat testing.
5. Conclusions
We conclude that in our population CF females do not
experience higher mortality than males. However, due to the
disease, females lose the expected survival advantage over
males occurring in the general population at this age. We do not
exclude, however, that differences in mortality will establish
after adolescence and, since speculations have arisen that
female sex hormones can impair function of alternative chloride
channels [19,20], it would be interesting to analyze survival
patterns after puberty.
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